Oncology Experts

Christian S. Hinrichs

Experimental Transplantation and Immunology Branch, CCR
National Cancer Institute
United States of America


Dr. Hinrichs received his B.A. and M.D. degrees from the combined 6-year program at the University of Missouri - Kansas City (UMKC). He completed a residency in general surgery at UMKC followed by a fellowship in surgical oncology at Roswell Park Cancer Institute. He then came to the Surgery Branch at the National Cancer Institute (NCI) as a surgical oncology fellow and studied tumor immunology in the laboratory of Dr. Nicholas P. Restifo. Subsequently he completed an internal medicine residency at George Washington University and a medical oncology fellowship with the Medical Oncology Branch, CCR. Dr. Hinrichs conducts translational research and clinical trials to develop T-cell therapies for cancers caused by human papillomaviruses. Dr. Hinrichs researches immunotherapy for HPV+ cancers, which include cervical, oropharyngeal, anal, vulvar, vaginal, and penile malignancies. He has discovered personalized cellular and gene therapies for HPV+ cancers. His laboratory is studying why these treatments work in some patients and not in others and is using what is learned to innovate more effective therapies.

Research Interest

1) Immunotherapy, 2) Cell therapy, 3) Human papillomavirus, 4) Cervical cancer, 5) Oropharyngeal cancer, 6) anal cancer, 7) discover and develop novel T cell therapies for the treatment of patients with cancer, 8) Biomedical Engineering and Biophysics, 9) Cancer Biology, 10) Clinical Research, 11) Immunology, 12) Virology


  • Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

  • Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.

  • Complete regression of metastatic cervical cancer following treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Global Experts from United States of America

Global Experts in Subject

Share This Profile